{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:34:27Z","timestamp":1791646467093,"version":"4.3.4"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Patients with atrial fibrillation (AF) and liver disease, particularly cirrhosis, are frequently excluded from anticoagulation trials, leaving the optimal therapeutic strategy uncertain.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study aimed to compare the effectiveness and safety of direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs) in patients with AF and liver disease. We systematically searched the PubMed, Cochrane Library, Medline, and Embase databases for relevant studies published up to November 2024.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Fourteen studies, involving 44,848 participants, were included. Compared to VKAs, DOACs were associated with significantly lower risks of major bleeding (risk ratio [RR]: 0.64, 95% confidence interval [CI]: 0.55\u20130.75; P &amp;lt; 0.0001), intracranial bleeding (RR: 0.43, 95% CI: 0.33\u20130.56; P &amp;lt; 0.0001), gastrointestinal (GI) bleeding (RR: 0.72, 95% CI: 0.59\u20130.89; P = 0.002), and all-cause mortality (RR: 0.83, 95% CI: 0.70\u20130.98; P = 0.03). No significant difference was observed in ischemic stroke\/systemic embolism (RR: 0.77, 95% CI: 0.52\u20131.13; P = 0.19). In patients with cirrhosis, DOACs were similarly superior for major bleeding, GI bleeding, and intracranial bleeding. Subgroup analyses revealed that apixaban demonstrated a more favorable safety profile than rivaroxaban in patients with liver disease, whereas both agents showed comparable effectiveness and safety in cirrhotic patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>DOACs are safer and equally effective alternatives to VKAs in patients with AF and liver disease, including those with cirrhosis. In patients with liver disease, apixaban may offer additional safety benefits compared with rivaroxaban. However, in patients with cirrhosis, the effectiveness and safety profiles of the two drugs are similar.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic review registration<\/jats:title><jats:p><jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD42024623387<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1620394","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T04:10:33Z","timestamp":1752466233000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Effectiveness and safety of direct oral anticoagulants versus vitamin K antagonists in atrial fibrillation patients with liver disease: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Qiang","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhichun","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanzi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuansu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jhep.2018.09.014","article-title":"Burden of liver diseases in the world","volume":"70","author":"Asrani","year":"2019","journal-title":"J. Hepatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ"},{"key":"B3","doi-asserted-by":"publisher","first-page":"265","DOI":"10.5114\/ceh.2023.130605","article-title":"Assessment of the efficiency and safety of anti-coagulation therapy in patients with liver cirrhosis and atrial fibrillation","volume":"9","author":"Baylo","year":"2023","journal-title":"Clin. Exp. Hepatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1161\/01.cir.98.10.946","article-title":"Impact of atrial fibrillation on the risk of death: the framingham heart study","volume":"98","author":"Benjamin","year":"1998","journal-title":"Circulation"},{"key":"B5","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.jhep.2012.12.005","article-title":"The burden of liver disease in Europe: a review of available epidemiological data","volume":"58","author":"Blachier","year":"2013","journal-title":"J. Hepatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.121.056355","article-title":"Direct oral anticoagulants versus warfarin in patients with atrial fibrillation: patient-level network meta-analyses of randomized clinical trials with interaction testing by age and sex","volume":"145","author":"Carnicelli","year":"2022","journal-title":"Circulation"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e017559","DOI":"10.1161\/JAHA.120.017559","article-title":"Direct oral anticoagulant use: a practical guide to common clinical challenges","volume":"9","author":"Chen","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"B8","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1093\/ehjcvp\/pvab032","article-title":"Anticoagulation in atrial fibrillation and liver disease: a pooled-analysis of >20 000 patients","volume":"8","author":"Chen","year":"2022","journal-title":"Eur. Heart J-Card Pha"},{"key":"B9","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1161\/STROKEAHA.118.023093","article-title":"Outcomes after use of Standard- and low-dose non-vitamin K oral anticoagulants in Asian patients with atrial fibrillation","volume":"50","author":"Cho","year":"2019","journal-title":"Stroke"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.15420\/ecr.2020.43","article-title":"Direct oral anticoagulants in Asian patients with atrial fibrillation: consensus recommendations by the Asian Pacific society of cardiology on strategies for thrombotic and bleeding risk management","volume":"16","author":"Chong","year":"2021","journal-title":"Eur. Cardiol. Rev."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0000000000002089","article-title":"Efficacy and safety of direct oral anticoagulants versus warfarin in patients with atrial fibrillation and liver cirrhosis","author":"Chou","year":"2024","journal-title":"J. Clin. Gastroenterol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"20","DOI":"10.7326\/M21-0717","article-title":"Risk for recurrent venous thromboembolism and bleeding with apixaban compared with rivaroxaban: an analysis of real-world data","volume":"175","author":"Dawwas","year":"2022","journal-title":"Ann. Intern Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.thromres.2024.03.024","article-title":"Effectiveness and safety of direct oral anticoagulants among patients with non-valvular atrial fibrillation and liver disease: a multinational cohort study","volume":"237","author":"Douros","year":"2024","journal-title":"Thromb. Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.jhep.2021.09.003","article-title":"EASL clinical practice guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis","volume":"76","year":"2022","journal-title":"J. Hepatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s40268-021-00359-y","article-title":"Apixaban pharmacokinetics and pharmacodynamics in subjects with mild or moderate hepatic impairment","volume":"21","author":"Frost","year":"2021","journal-title":"Drugs R. D."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1001\/jama.285.18.2370","article-title":"Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and risk factors in atrial fibrillation (ATRIA) study","volume":"285","author":"Go","year":"2001","journal-title":"Jama-J Am. Med. Assoc."},{"key":"B18","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/ejh.13045","article-title":"Safety of direct oral anticoagulants vs warfarin in patients with chronic liver disease and atrial fibrillation","volume":"100","author":"Goriacko","year":"2018","journal-title":"Eur. J. Haematol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s40262-013-0034-0","article-title":"Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment","volume":"52","author":"Graff","year":"2013","journal-title":"Clin. Pharmacokinet."},{"key":"B20","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1007\/s10557-020-07065-y","article-title":"Efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation and liver disease: a meta-analysis and systematic review","volume":"35","author":"Huang","year":"2021","journal-title":"Cardiovasc Drug Ther."},{"key":"B22","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1160\/TH14-03-0228","article-title":"Non-vitamin K antagonist oral anticoagulants (NOACs): no longer new or novel","volume":"111","author":"Husted","year":"2014","journal-title":"Thromb. Haemost."},{"key":"B23","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1161\/CIRCULATIONAHA.122.063195","article-title":"Use of direct-acting oral anticoagulants in patients with atrial fibrillation and chronic liver disease","volume":"147","author":"Hydes","year":"2023","journal-title":"Circulation"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.7326\/M21-1474","article-title":"Rivaroxaban is associated with higher rates of gastrointestinal bleeding than other direct oral anticoagulants: a nationwide propensity score-weighted study","volume":"174","author":"Ingason","year":"2021","journal-title":"Ann. Intern Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jacc.2023.08.017","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American college of cardiology\/american heart association joint committee on clinical practice guidelines","volume":"83","author":"Joglar","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.jtha.2023.09.020","article-title":"Anticoagulation in chronic kidney disease: current status and future perspectives","volume":"22","author":"Jones","year":"2024","journal-title":"J. Thromb. Haemost."},{"key":"B27","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/rth2.12002","article-title":"Current practice patterns and patient persistence with anticoagulant treatments for cancer-associated thrombosis","volume":"1","author":"Khorana","year":"2017","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur. Heart J."},{"key":"B29","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/bcp.12054","article-title":"Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct factor Xa inhibitor","volume":"76","author":"Kubitza","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1161\/CIRCULATIONAHA.122.060687","article-title":"Comparative effectiveness and safety of direct oral anticoagulants and warfarin in patients with atrial fibrillation and chronic liver disease: a nationwide cohort study","volume":"147","author":"Lawal","year":"2023","journal-title":"Circulation"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e011112","DOI":"10.1161\/JAHA.118.011112","article-title":"Effectiveness and safety of non-vitamin K antagonist oral anticoagulant and warfarin in cirrhotic patients with nonvalvular atrial fibrillation","volume":"8","author":"Lee","year":"","journal-title":"J. Am. Heart Assoc."},{"key":"B32","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1016\/j.jacc.2019.04.052","article-title":"Direct oral anticoagulants in patients with atrial fibrillation and liver disease","volume":"73","author":"Lee","year":"","journal-title":"J. Am. Coll. Cardiol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1055\/s-0043-1770100","article-title":"Risk of bleeding in liver cirrhosis receiving direct oral anticoagulants: a systematic review and meta-analysis","volume":"123","author":"Li","year":"2023","journal-title":"Thromb. Haemost."},{"key":"B34","doi-asserted-by":"publisher","first-page":"102534","DOI":"10.1016\/j.jceh.2025.102534","article-title":"Efficacy and safety of direct oral anticoagulants compared to vitamin K antagonists for atrial fibrillation in patients with liver cirrhosis: an update systematic review and meta-analysis","volume":"15","author":"Miranda Maria","year":"2025","journal-title":"J. Clin. Exp. Hepatol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"Plos Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1016\/j.cgh.2020.08.007","article-title":"Rates of bleeding and discontinuation of direct oral anticoagulants in patients with decompensated cirrhosis","volume":"19","author":"Mort","year":"2021","journal-title":"Clin. Gastroenterol. H."},{"key":"B37","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s11239-021-02424-4","article-title":"Safety of direct oral anticoagulants in patients with mild to moderate cirrhosis: a systematic review and meta-analysis","volume":"52","author":"Nisly","year":"2021","journal-title":"J. Thromb. Thrombolys"},{"key":"B38","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1002\/hep.31646","article-title":"Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 practice guidance by the American association for the study of liver diseases","volume":"73","author":"Northup","year":"2021","journal-title":"Hepatology"},{"key":"B39","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.dib.2018.01.109","article-title":"Data on incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants","volume":"17","author":"Pastori","year":"2018","journal-title":"Data Brief."},{"key":"B40","doi-asserted-by":"publisher","first-page":"101116","DOI":"10.1016\/j.jhepr.2024.101116","article-title":"Direct oral anticoagulants in cirrhosis: rationale and current evidence","volume":"6","author":"Pereira Portela","year":"2024","journal-title":"JHEP Rep."},{"key":"B41","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jacc.2019.04.061","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation and history of liver disease","volume":"74","author":"Qamar","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1001\/jama.2021.21222","article-title":"Association of rivaroxaban vs apixaban with major ischemic or hemorrhagic events in patients with atrial fibrillation","volume":"326","author":"Ray","year":"2021","journal-title":"Jama-j Am. Med. Assoc."},{"key":"B43","doi-asserted-by":"publisher","first-page":"102039","DOI":"10.1016\/j.eclinm.2023.102039","article-title":"Patterns of oral anticoagulant use and outcomes in Asian patients with atrial fibrillation: a post-hoc analysis from the GLORIA-AF registry","volume":"63","author":"Romiti","year":"2023","journal-title":"EClinicalMedicine"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2023.7843","article-title":"Direct oral anticoagulants vs low-molecular-weight heparin and recurrent VTE in patients with cancer: a randomized clinical trial","volume":"329","author":"Schrag","year":"2023","journal-title":"Jama-j Am. Med. Assoc."},{"key":"B45","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J. Thromb. Haemost."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1016\/j.jhep.2023.06.001","article-title":"A major research gap: the use of anticoagulants in cirrhosis","volume":"79","author":"Senzolo","year":"2023","journal-title":"J. Hepatol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/hep.31264","article-title":"Mortality and hepatic decompensation in patients with cirrhosis and atrial fibrillation treated with anticoagulation","volume":"73","author":"Serper","year":"2021","journal-title":"Hepatology"},{"key":"B48","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/S1473-3099(05)70216-4","article-title":"Global epidemiology of hepatitis C virus infection","volume":"5","author":"Shepard","year":"2005","journal-title":"Lancet Infect. Dis."},{"key":"B49","doi-asserted-by":"publisher","first-page":"e026863","DOI":"10.1161\/JAHA.122.026863","article-title":"Prescribing trends of oral anticoagulants in US patients with cirrhosis and nonvalvular atrial fibrillation","volume":"12","author":"Simon","year":"2023","journal-title":"J. Am. Heart Assoc."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.7326\/M23-3067","article-title":"Comparative effectiveness and safety of apixaban, rivaroxaban, and warfarin in patients with cirrhosis and atrial fibrillation: a nationwide cohort study","volume":"177","author":"Simon","year":"2024","journal-title":"Ann. Intern Med."},{"key":"B51","doi-asserted-by":"publisher","first-page":"10742484241256271","DOI":"10.1177\/10742484241256271","article-title":"Assessing safety of anticoagulation for atrial fibrillation in patients with cirrhosis: a real-world outcomes study","volume":"29","author":"Song","year":"2024","journal-title":"J. Cardiovasc Pharm. T"},{"key":"B52","doi-asserted-by":"publisher","first-page":"102240","DOI":"10.1016\/j.rpth.2023.102240","article-title":"Use of direct oral anticoagulants for venous thromboembolism treatment at extremes of body weight, renal and liver function: an illustrated review","volume":"7","author":"Speed","year":"2023","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace."},{"key":"B54","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"B55","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1056\/NEJMra1011170","article-title":"The coagulopathy of chronic liver disease","volume":"365","author":"Tripodi","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"B56","doi-asserted-by":"publisher","first-page":"e009263","DOI":"10.1161\/JAHA.118.009263","article-title":"Efficacy and safety of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with impaired liver function: a retrospective cohort study","volume":"7","author":"Wang","year":"2018","journal-title":"J. Am. Heart Assoc."},{"key":"B57","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s11427-024-2722-2","article-title":"Epidemiology of liver diseases: global disease burden and forecasted research trends","volume":"68","author":"Xiao","year":"2025","journal-title":"Sci. China Life Sci."},{"key":"B58","doi-asserted-by":"publisher","first-page":"555","DOI":"10.3904\/kjim.2020.622","article-title":"Safety of direct oral anticoagulants compared to warfarin in cirrhotic patients with atrial fibrillation","volume":"37","author":"Yoo","year":"2022","journal-title":"Korean J. Intern Med."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1016\/j.cgh.2023.04.015","article-title":"The global burden of liver disease","volume":"21","author":"Younossi","year":"2023","journal-title":"Clin. Gastroenterol. H."},{"key":"B60","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1080\/17843286.2022.2108259","article-title":"Safety of direct oral anticoagulants in patients with liver disease: a systematic review and meta-analysis","volume":"78","author":"Zhao","year":"2023","journal-title":"ACTA Clin. Belg"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1620394\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T04:10:35Z","timestamp":1752466235000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1620394\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,14]]},"references-count":59,"alternative-id":["10.3389\/fphar.2025.1620394"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1620394","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,14]]},"article-number":"1620394"}}